Skip to main content
. 2022 Aug 24;16(1):30–40. doi: 10.1093/ckj/sfac187

Figure 4:

Figure 4:

Improvement in itch severity and itch-related QoL with difelikefalin versus placebo, measured by (a) ≤3-point improvement in WI-NRS, (b) weekly improvement in WI-NRS, (c) Skindex-10 and (d) 5-D itch scale. SE, standard error. References: Fishbane et al. N Engl J Med 2020;382:222–32; Wooldridge et al. J Am Soc Nephrol 2020;31:22–23.